LUND, Sweden, Nov. 28, 2018 /PRNewswire/ -- Camurus announced today that the Australian Therapeutic Goods Administration (TGA) has approved the company's lead products Buvidal® Weekly and Buvidal® ...

- Individualized treatment of opioid dependence with weekly and monthly Buvidal ® was well-tolerated and effective, with a high (73.6%) patient retention across the 48-week study - 83.4% of ...

Phase 3 post-hoc analysis indicates less fentanyl and overall illicit opioid use for weekly/monthly buprenorphine depots versus daily standard treatment in a difficult to treat patient population LUND ...

Camurus, a Swedish research-based pharmaceutical company, announced that the European Commission (EC) has approved weekly and monthly Buvidal (prolonged release buprenorphine) for the treatment of ...

LUND, Sweden, March 26, 2021 /PRNewswire/ -- Camurus today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency's (EMA) has issued a positive ...

LUND, Sweden , May 10, 2021 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) announces today the publication in JAMA Network Open of results from a 24-week, randomized, controlled trial (DEBUT) comparing ...

Camurus, a Swedish, science-led biopharmaceutical company, announced topline results from the 24-week, randomized, controlled, open-label, DEBUT study of weekly and monthly Buvidal (prolonged-release ...

A drug used in a pilot scheme to help prisoners affected by heroin addiction is to be rolled out across Scotland. Buvidal acts as a replacement treatment for methadone, with patients receiving an ...

LUND, Sweden, Nov. 22, 2018 /PRNewswire/ -- Camurus announced today that the European Commission (EC) has approved weekly and monthly Buvidal® (prolonged release buprenorphine) for the treatment of ...

- Buvidal(R) is the first long-acting medicine approved in the EU for the treatment of opioid dependence in adults and adolescents Camurus announced today that the European Commission has granted ...